Yarrow Bioscience, Inc. Common Stock
YARW
81 hedge funds and large institutions have $154M invested in Yarrow Bioscience, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 23 reducing their positions, and 31 closing their positions.
415% more call options, than puts
Call options by funds: $845K | Put options by funds: $164K
11% more capital invested
Capital invested by funds: $138M → $154M (+$15.6M)
0.03% more ownership
Funds ownership: 0.01% → 0.05% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 23
17% less funds holding
Funds holding: 98 → 81 (-17)
52% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$8.5M |
| 2 |
BlackRock
New York
|
+$4.92M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.86M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.86M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$9.43M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.28M |
| 3 |
Squarepoint
New York
|
-$950K |
| 4 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$812K |
| 5 |
Renaissance Technologies
New York
|
-$725K |
YARW Hedge Fund Activity: Q1 2021 in Review
81 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q1 2021, worth a combined $154M — up 11% from $138M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of YARW and 15 opened new positions — a net loss of 16 holders — while 23 trimmed existing stakes and 20 added.
The largest buyer was Perceptive Advisors, adding an estimated $8.5M. The largest seller was 683 Capital Management, exiting entirely with an estimated $9.43M sold.
- 81 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q1 2021, down from 98 in Q4 2020.
- Funds reported $154M of Yarrow Bioscience, Inc. Common Stock stock for Q1 2021, up 11% quarter-over-quarter.
- 15 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q1 2021 and 31 closed out, a net change of -16 holders.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q1 2021 was Perceptive Advisors, an estimated $8.5M added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q1 2021 was 683 Capital Management, an estimated $9.43M sold.
Based on aggregated 13F filings for Q1 2021.